{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:42:47Z","timestamp":1788392567168,"version":"build-2803163510"},"reference-count":10,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"F. Hoffman-La Roche Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III\/IV TAIL study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03285763\">NCT03285763<\/jats:ext-link>) evaluated atezolizumab monotherapy in patients with previously treated NSCLC, including those with Eastern Cooperative Oncology Group performance status of 2, severe renal impairment, prior anti-programmed death 1 therapy, autoimmune disease, and age \u226575 years. Patients received atezolizumab intravenously (1200 mg) every 3 weeks. At data cut-off for final analysis, the median follow-up was 36.1 (range 0.0\u201342.3) months. Treatment-related (TR) serious adverse events (SAEs) and TR immune-related adverse events (irAEs) were the coprimary endpoints. Secondary endpoints included overall survival (OS), progression-free survival (PFS), overall response rate, and duration of response. Safety and efficacy in key patient subgroups were also assessed. TR SAEs and TR irAEs occurred in 8.0% and 9.4% of patients, respectively. No new safety signals were documented. In the overall population, median OS and PFS (95% CI) were 11.2 months (8.9 to 12.7) and 2.7 months (2.3 to 2.8), respectively. TAIL showed that atezolizumab has a similar risk-benefit profile in clinically diverse patients with previously treated NSCLC, which may guide treatment decisions for patients generally excluded from pivotal clinical trials.<\/jats:p>","DOI":"10.1136\/jitc-2022-005581","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T10:15:22Z","timestamp":1669803322000},"page":"e005581","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03285763","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03285763","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-4257","authenticated-orcid":false,"given":"Andrea","family":"Ardizzoni","sequence":"first","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Azevedo","sequence":"additional","affiliation":[{"name":"Oncology Service, Unidade de Pesquisa Clinica, Hospital de Cl\u00ednicas de Porto Alegre, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Rubio-Viqueira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Quir\u00f3nsalud Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodriguez-Abreu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alatorre-Alexander","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J M","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, Rijnstate Hospital, Arnhem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Syrigos","sequence":"additional","affiliation":[{"name":"3rd Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elen","family":"H\u00f6glander","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kaul","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tolson","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"Hu","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Kristian","family":"Vollan","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Newsom-Davis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"2025100308422667000_10.11.e005581.1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001865"},{"key":"2025100308422667000_10.11.e005581.2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100308422667000_10.11.e005581.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2025100308422667000_10.11.e005581.4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.18.02118","article-title":"Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence","volume":"37","author":"Passaro","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100308422667000_10.11.e005581.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.010"},{"key":"2025100308422667000_10.11.e005581.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2025100308422667000_10.11.e005581.7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-2600(18)30500-9","article-title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study","volume":"7","author":"Leighl","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100308422667000_10.11.e005581.8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025100308422667000_10.11.e005581.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.022"},{"key":"2025100308422667000_10.11.e005581.10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:42:32Z","timestamp":1759506152000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,30]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jitc-2022-005581"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005581","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}